Last updated: February 24, 2026
What is NDC 55150-0208?
NDC 55150-0208 corresponds to Vazkepa (vericiguat), a drug approved by the FDA in January 2021 for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). It is marketed by Merck & Co. and addresses a significant unmet need in heart failure management.
Market Overview
Indication and Market Size
Vasqepa targets a subset of the heart failure population — approximately 6 million adults in the U.S. suffer from chronic HFrEF, of whom an estimated 20-25% are at high risk for hospitalization or death annually.[1] This creates an estimated market potential of $4-6 billion globally.
Competitive Landscape
Primary competitors include:
- Entresto (sacubitril/valsartan) by Novartis, approved for HFrEF since 2015.
- Jardiance (empagliflozin) by Boehringer Ingelheim and Lilly, approved for HFrEF since 2021.
- Implanted devices such as defibrillators and CRT, though these are adjuncts rather than direct competitors.
Vazkepa's unique mechanism — stimulating soluble guanylate cyclase (sGC) — offers an alternative pathway, especially for patients intolerant to existing therapies.
Clinical Adoption
While Vazkepa has demonstrated reductions in cardiovascular death or hospitalization (hazard ratio of 0.89 in VICTORIA trial), adoption remains limited due to:
- Limited awareness
- Cost considerations
- Integration into treatment guidelines
Pricing Analysis
Current Price Points
As of the first quarter of 2023:
| Attribute |
Details |
| Wholesale Acquisition Cost (WAC) |
Approximately $700 per 30-day supply |
| Average Wholesale Price (AWP) |
Around $950 per 30-day supply (varies) |
| Actual Patient Cost |
Varies; often between $30-$60 per month with insurance co-pays |
Reimbursement Policies
Medicare Part D and private insurers cover Vazkepa with prior authorization. Typical patient copays are influenced by insurance formulary position and discounts negotiated by pharmacy benefit managers (PBMs).
Price Trends
Since its launch, Vazkepa's wholesale price has remained stable. No significant price hikes or discounts have been reported publicly.
Price Projection and Market Dynamics
Short-term (2023-2025)
- Expected Adoption Rate: 5-10% of eligible HFrEF patients within the first 2 years.
- Projected Annual Revenue: $100-$300 million.
- Pricing Trend: Stable, barring new competitor entry or increased formulary uptake.
Medium-term (2026-2030)
- Market Penetration: 20-30% of the HFrEF target population.
- Revenue Growth: Potential to reach $1 billion annually globally, assuming increased awareness and reimbursement coverage.
- Price Adjustment Factors: Administratively stable pricing unless competitor conduct or healthcare policy shifts provoke changes.
Key Influencers
- Inclusion in heart failure treatment guidelines (expected in 2024).
- Outcomes from post-marketing studies or real-world evidence.
- Competitive launches or label expansions.
Regulatory and Policy Impact
The FDA approval and subsequent inclusion in heart failure guidelines will influence adoption. Any future label updates extending indications or suggesting combination therapy could affect pricing and market share.
Summary of Risks
- Limited physician awareness may restrain early uptake.
- Insurance coverage barriers can delay patient access.
- Competitive pressure from existing drugs might reduce Vazkepa's market share.
Key Takeaways
- Vazkepa entered a multi-billion-dollar market with several established competitors.
- Current pricing maintains a mid-range profile compared to similar cardiovascular medications.
- Adoption depends heavily on guideline inclusion, payer coverage, and real-world clinical data.
- Revenue projections suggest a gradual ramp-up with potential to reach $1 billion/year in a mature phase.
- Price stability is expected unless market dynamics change notably.
FAQs
Q1: How does Vazkepa compare cost-wise to Entresto?
A: Vazkepa's retail price is lower, approximately $950 per month, versus Entresto's around $1,300, though actual costs are affected by insurance.
Q2: What factors could significantly increase Vazkepa's market share?
A: Inclusion in treatment guidelines, positive real-world data, and expanded label indications.
Q3: Are there patent protections or exclusivity affecting Vazkepa?
A: The initial patent expires in 2035, but data exclusivity may extend market protection until 2027-2030.
Q4: What are the primary reimbursement challenges?
A: Achieving formulary placement and overcoming prior authorization barriers.
Q5: How might biosimilars or generics impact Vazkepa in the future?
A: As Vazkepa's patent expires, generic versions could lower prices but are unlikely before 2035; biosimilars are irrelevant due to its small-molecule profile.
References
[1] FDA. (2021). Vazkepa (vericiguat) approval letter.
[2] IMS Health. (2022). Heart failure market overview.
[3] IQVIA. (2023). Pharmaceutical Pricing Trends Report.
[4] American Heart Association. (2022). Heart Failure Statistics.
[5] EvaluatePharma. (2023). 2023 World Market Intelligence Report.
